News and Events

Immunotherapy after surgery helps people with high-risk bladder cancer live cancer-free longer

Results from a large CCR clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following surgical removal of the bladder. Researchers led by Andrea B. Apolo, M.D., Senior Investigator in the Genitourinary Malignancies Branch, found that postsurgical treatment with pembrolizumab (Keytruda), which is approved by the Food and Drug Administration (FDA) for treating at least 18 different cancers, was superior compared with observation.

NIH study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry

CCR researchers led by Stefan Ambs, Ph.D., M.P.H., Senior Investigator in the Laboratory of Human Carcinogenesis, found that West African genetic ancestry was associated with increased prostate cancer among men living in disadvantaged neighborhoods but not among men living in more affluent neighborhoods. The findings suggest that neighborhood environment may play a role in determining how genetic ancestry influences prostate cancer risk.

Opting for a Novel Combination Treatment for Resistant Aggressive B-Cell Lymphoma

In 2020, Justin enrolled in a CCR trial testing a five-drug combination treatment called ViPOR for non-Hodgkin lymphoma. Four years later, his doctor Christopher J. Melani, M.D., Assistant Research Physician in the Lymphoid Malignancies Branch, describes Justin as likely cancer-free.

Daniel Larson appointed Chief of the Laboratory of Receptor Biology and Gene Expression

The CCR community congratulates Daniel R. Larson, Ph.D., who has been appointed Chief of the Laboratory of Receptor Biology and Gene Expression. Larson’s laboratory’s goal is to understand gene expression in eukaryotic cells, starting from the mechanistic behavior of individual macromolecules and proceeding to their regulation in cells and tissue. His current work is focused on applying experimental and theoretical approaches to the study of hematopoiesis in health and disease through the trans-NIH Myeloid Malignancies Program.

Clinical trial researching immunotherapy for solid tumors

A clinical trial led by Kevin C. Conlon, M.D., Associate Research Physician in the Women’s Malignancies Branch, is researching immunotherapy for solid tumors.

Clinical trial researching drug therapy for central nervous system tumors

A clinical trial led by Marta Penas-Prado, M.D., M.Sc., Senior Clinician in the Neuro-Oncology Branch, is researching drug therapy for tumors of the central nervous system.

Understanding the Risk of Second Cancers After CAR T-Cell Therapy

Two recent reports in the New England Journal of Medicine are seeking to determine if there may be a causal link between CAR T-cell treatment and second cancers. In this Q&A, Stephanie L. Goff, M.D., Senior Research Physician in the Surgery Branch, discusses the findings and what this issue may mean in general for patients and this area of research.

Clinical trial researching immunotherapy for throat cancer

A clinical trial led by Clint T. Allen, M.D., Senior Investigator in the Surgical Oncology Program, is researching combination immunotherapy for HPV-associated throat cancer.

2025 NCI RNA Biology Symposium

Date: April 3-4, 2025
Location: Building 45, Natcher Auditorium

The mission of the NCI RNA Biology Initiative is to create an interdisciplinary environment that promotes the swift exchange of information and expertise regarding the structure, function, and biological significance of RNA. Our objective is to leverage our collective knowledge to advance the development of novel diagnostics and therapies. This biennial symposium, organized by the NCI RNA Biology Initiative, offers the opportunity to learn about new advances in multiple areas of RNA biology, to share research and to network with leading scientists, and to discuss the use and implications of these advances for clinical medicine.

Clinical trial researching CAR T-cell therapy for certain large B-cell lymphomas

A clinical trial led by Nirali N. Shah, M.D., M.H.Sc., Lasker Clinical Research Scholar in the Pediatric Oncology Branch, is studying the use of CAR T-cell therapy for relapsed or refractory large B-cell lymphoma (LBCL).

Breadcrumb